↓ Skip to main content

Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer

Overview of attention for article published in Nature Medicine, June 2018
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#18 of 7,132)
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

news
150 news outlets
blogs
17 blogs
policy
1 policy source
twitter
1440 tweeters
patent
1 patent
facebook
36 Facebook pages
googleplus
2 Google+ users
reddit
1 Redditor
video
3 video uploaders

Readers on

mendeley
890 Mendeley
citeulike
1 CiteULike
Title
Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer
Published in
Nature Medicine, June 2018
DOI 10.1038/s41591-018-0040-8
Pubmed ID
Authors

Nikolaos Zacharakis, Harshini Chinnasamy, Mary Black, Hui Xu, Yong-Chen Lu, Zhili Zheng, Anna Pasetto, Michelle Langhan, Thomas Shelton, Todd Prickett, Jared Gartner, Li Jia, Katarzyna Trebska-McGowan, Robert P. Somerville, Paul F. Robbins, Steven A. Rosenberg, Stephanie L. Goff, Steven A. Feldman

Abstract

Immunotherapy using either checkpoint blockade or the adoptive transfer of antitumor lymphocytes has shown effectiveness in treating cancers with high levels of somatic mutations-such as melanoma, smoking-induced lung cancers and bladder cancer-with little effect in other common epithelial cancers that have lower mutation rates, such as those arising in the gastrointestinal tract, breast and ovary1-7. Adoptive transfer of autologous lymphocytes that specifically target proteins encoded by somatically mutated genes has mediated substantial objective clinical regressions in patients with metastatic bile duct, colon and cervical cancers8-11. We present a patient with chemorefractory hormone receptor (HR)-positive metastatic breast cancer who was treated with tumor-infiltrating lymphocytes (TILs) reactive against mutant versions of four proteins-SLC3A2, KIAA0368, CADPS2 and CTSB. Adoptive transfer of these mutant-protein-specific TILs in conjunction with interleukin (IL)-2 and checkpoint blockade mediated the complete durable regression of metastatic breast cancer, which is now ongoing for >22 months, and it represents a new immunotherapy approach for the treatment of these patients.

Twitter Demographics

The data shown below were collected from the profiles of 1,440 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 890 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 890 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 229 26%
Student > Ph. D. Student 176 20%
Student > Master 76 9%
Student > Bachelor 70 8%
Other 60 7%
Other 149 17%
Unknown 130 15%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 192 22%
Medicine and Dentistry 148 17%
Agricultural and Biological Sciences 137 15%
Immunology and Microbiology 116 13%
Engineering 24 3%
Other 103 12%
Unknown 170 19%

Attention Score in Context

This research output has an Altmetric Attention Score of 2324. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 February 2020.
All research outputs
#1,138
of 15,630,269 outputs
Outputs from Nature Medicine
#18
of 7,132 outputs
Outputs of similar age
#22
of 280,655 outputs
Outputs of similar age from Nature Medicine
#1
of 89 outputs
Altmetric has tracked 15,630,269 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 7,132 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 55.2. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 280,655 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 89 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.